Sakara Digital https://validator.w3.org/feed/docs/rss2.html Chain of Identity for Cell Therapies: Digital Traceability from Patient to Product and Back The Purolea Letter: What Pharma’s First AI Warning Means for GxP Compliance Cell and Gene Therapy IT Infrastructure: Building Digital Systems for the Most Complex Therapies Wearable Device Data in Clinical Evidence: Leveraging Real-World Data for Regulatory Submissions Data Integrity and ALCOA+ in the Digital Age: Modernizing Compliance for Cloud and AI Systems Multi-Omics Data Integration: Technology Architecture for Precision Medicine and Biomarker Discovery Real-World Evidence Strategy: Building RWE Capabilities for Regulatory and Commercial Decision-Making Master Data Management for Life Sciences: Creating a Single Source of Truth Across Global Operations Data Lakehouse Architecture for Pharma: Unifying Clinical, Manufacturing, and Commercial Data Code Without Compassion Clean Data, Clear Path: What Data Readiness Means for AI in Life Sciences FAIR Data Principles for Life Sciences: Building Findable, Accessible, Interoperable, and Reusable Data Assets A Roadmap for AI Readiness in Pharma: Building the Foundations for Trustworthy, Scalable AI Why AI Fails in Pharma: The Real Reason Isn’t the Technology The Five Pillars of Data Quality Every Pharma Leader Must Master 20 Seconds to Smarter Business Data Quality & Integrity Services The Velocity of Lasting Change, Part 1 – The Funeral of Innovation Strategic Excellence White Papers Operational Excellence Workshops The Velocity of Lasting Change, Part 2 – The Cost of Compliance The Velocity of Lasting Change, Part 3 – The Myth of Readiness Strategic Partnerships Annex 11 and Annex 22 Revisions: Preparing GxP Systems for EMA’s New AI and Data Integrity Rules Understanding AI Maturity: Part 1 – The AI Maturity Model – From Ad Hoc to Enterprise Ecosystems FDA Computer Software Assurance (CSA): A Practical Guide to Risk-Based Validation EU Gene Therapy Standards: Navigating EMA’s Evolving Manufacturing and Quality Requirements Selecting Software Vendors for GxP Regulated Industries: A Practical Guide Understanding AI Maturity: Part 2 – Stage 1: Ad Hoc Use – Where Curiosity Meets Risk Digital Twins for Pharmaceutical Manufacturing: Building Virtual Process Models That Drive Real Results Agentic AI in Pharma: Moving Beyond Chatbots to Autonomous Workflows Strong Foundations: Why Process Discipline Precedes AI Success Success Stories Our Engagement Approach Agility in AI Leadership – Why Inclusion Shapes Adoption Understanding AI Maturity: Part 3 – Stage 2: Localized Projects Understanding AI Maturity: Part 4 – Stage 3: Programmatic Use Code Without Compassion, Part 1: Fired by Bot — The Amazon Flex Case Understanding AI Maturity: Part 5 – Stage 4: Enterprise Ecosystems The Vanishing First Rung: How AI Is Reshaping Entry-Level Work Code Without Compassion, Part 2: When Algorithms Manage Humans Code Without Compassion, Part 3: Due Process in the Age of AI Code Without Compassion, Part 4: Designing for Dignity The EU AI Act Hits Enforcement: What Life Sciences Companies Must Do Now Code Without Compassion, Part 5: What Businesses Can Learn Building Editorial Systems for Life Sciences Organizations 5 Signs Your Quality System Needs a Tune-Up Built-In, Not Bolted On: The Case for Native Digital Adoption in Life Sciences Software Operational Excellence Frameworks for Life Sciences Organizations ATMP Manufacturing Automation: Scaling Cell and Gene Therapy Production Through Digital Innovation